Catalyst Event
Vertex Pharmaceuticals Inc (VRTX) · Other
From Akros U.S. Tech 100 Index (AUT100)
6/1/2026, 12:00:00 AM
The US FDA accepted the Biologics License Application (BLA) for povetacicept for the treatment of IgA nephropathy (IgAN) on June 1, 2026. This is estimated to have a medium market impact as a significant regulatory milestone. The agency set a PDUFA target action date of November 30, 2026, scheduled.
Korean Translation
2026년 6월 1일, 미국 FDA가 면역글로불린 A 신병증(IgAN) 치료제 포베타셉트(povetacicept)에 대한 생물의약품 허가 신청(BLA)을 접수함. 주요 규제 마일스톤 달성으로 중간 수준의 시장 영향이 예상됨. PDUFA 목표 조치일은 2026년 11월 30일로 예정됨.
Related Recent Events
Microchip Technology Inc (MCHP) · Earnings Release
Next quarterly earnings for Q1 2027 are expected to be released around August 6, 2026, expected. Low impact is estimated as this is a routine scheduling announcement.
8/6/2026, 12:00:00 AM
AppLovin Corporation (APP) · Earnings Release
AppLovin's Q2 2026 earnings release is expected around August 5, 2026, based on past reporting schedules expected. Low impact estimated as the announcement of a date typically precedes the actual market-moving results.
8/5/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
Q2 2026 earnings release and conference call scheduled.
8/4/2026, 12:00:00 AM
Cummins Inc. (CMI) · Earnings Release
Q2 2026 earnings release on 2026-08-04, for which high importance is estimated due to potential 10% price impact, is scheduled.
8/4/2026, 12:00:00 AM
KLA Corp (KLAC) · Earnings Release
Fiscal Q4 2026 earnings release on July 30, 2026, is expected to have a medium importance impact on the stock price, scheduled.
7/30/2026, 12:00:00 AM
Apple Inc (AAPL) · Earnings Release
Apple's Q3 2026 earnings release is expected on July 30, 2026; analysts forecast an EPS of approximately $1.86 forecasted. Low importance is estimated as the market impact is expected to be around 1%.
7/30/2026, 12:00:00 AM